



ASX Announcement

16 June 2020

## Results of Annual General Meeting

**Creso Pharma Limited (ASX:CPH)** ('Creso Pharma' or 'the Company') today held an Annual General Meeting of Members by virtual meeting facility, conducted from the offices of Azalea Consulting Pty Ltd, Suite 5 CPC, 145 Stirling Highway, Nedlands WA 6009.

All resolutions were determined by a poll.

The outcome of each resolution put to shareholders at the Annual General Meeting is set out in the Annexure which accompanies this release.

**Ends**

### Authority and Contact Details

This announcement has been authorised for release by Erlyn Dale, Joint Company Secretary.

For further information, please contact:

#### Investor Enquiries

EverBlu Capital

E: [info@everblucapital.com](mailto:info@everblucapital.com)

P: +61 2 8249 0000

#### Media Enquiries

Ben Jarvis | Six Degrees Group

E: [ben.jarvis@sdir.com.au](mailto:ben.jarvis@sdir.com.au)

P: +61 413 150 448

### About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso Pharma uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: [www.cresopharma.com](http://www.cresopharma.com)

# Disclosure of Proxy Votes

## Creso Pharma Limited

Annual General Meeting

Tuesday, 16 June 2020



**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)		
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of Remuneration Report	P	26,035,715	24,063,854 92.43%	1,645,762 6.32%	52,087	326,099 1.25%	24,689,953 93.75%	1,646,762 6.25%	52,087
2 Re-election of Director - Dr James Ellingford	P	57,387,688	56,596,237 98.62%	450,352 0.78%	8,502	341,099 0.59%	57,237,336 99.22%	450,352 0.78%	8,502
3 Approval of 7.1a Mandate	P	57,244,665	56,191,648 98.16%	697,075 1.22%	151,525	355,942 0.62%	56,847,590 98.79%	697,075 1.21%	151,525
4 Ratification of prior issue of Initial Collateral Shares to Lind under the Lind Convertible Securities Agreement	P	57,349,800	56,370,701 98.29%	636,487 1.11%	46,390	342,612 0.60%	57,013,313 98.90%	636,487 1.10%	46,390
5 Approval to issue Subsequent Collateral Shares to Lind under the Lind Convertible Securities Agreement	P	57,349,100	56,358,186 98.27%	648,302 1.13%	47,090	342,612 0.60%	57,000,798 98.88%	648,302 1.12%	47,090
6 Approval to issue Additional Collateral Shares to Lind under the Lind Convertible Securities Agreement	P	57,239,100	56,229,947 98.24%	666,541 1.16%	157,090	342,612 0.60%	56,872,559 98.84%	666,541 1.16%	157,090
7 Approval to issue Convertible Securities to Lind under the Lind Convertible Securities Agreement	P	57,352,853	56,241,115 98.06%	769,126 1.34%	43,337	342,612 0.60%	56,883,727 98.67%	769,126 1.33%	43,337



			Proxy Votes				Poll Results (if applicable)		
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
8 Ratification of prior issue of Additional Collateral Shares to the Nominee of L1 Capital	P	43,337,090	42,336,812 97.69%	657,666 1.52%	10,122	342,612 0.79%	42,979,424 98.49%	657,666 1.51%	10,122
9 Approval to issue Additional Tranche 1 Collateral Shares to L1 Capital under the original Convertible Securities Agreement	P	43,236,330	42,222,750 97.66%	670,968 1.55%	110,882	342,612 0.79%	42,865,362 98.46%	670,968 1.54%	110,882
10 Approval to issue Additional Tranche 1 Collateral Shares to Chifley under the original Convertible Securities Agreement	P	57,371,555	56,258,462 98.06%	770,481 1.34%	24,635	342,612 0.60%	56,901,074 98.66%	770,481 1.34%	24,635
11 Approval to issue Additional Tranche 1 Collateral Shares to Suburban Holdings	P	49,163,167	48,036,489 97.71%	777,066 1.58%	24,635	349,612 0.71%	48,686,101 98.43%	777,066 1.57%	24,635
12 Appointment of Auditor at AGM to fill vacancy	P	57,375,688	56,766,498 98.94%	258,091 0.45%	20,502	351,099 0.61%	57,417,597 99.55%	258,091 0.45%	20,502
13 Non-executive Directors' Remuneration	P	25,952,547	23,889,015 92.05%	1,705,573 6.57%	135,255	357,959 1.38%	24,546,974 93.50%	1,705,573 6.50%	135,255
14 Approval to issue Settlement Shares	P	57,383,988	56,369,308 98.23%	658,181 1.15%	12,202	356,499 0.62%	57,025,807 98.86%	658,181 1.14%	12,202

